An increased level of Id4 has been observed in basal-like breast cancer, triple-negative breast cancer [23], glioblastoma [24], primary serous ovarian cancer [25], and melanoma [26], leading to the qualification of Id4 as a proto-oncogene. This evidence concerns the gene ID4 and triple-negative breast carcinoma.